e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arvinas, Inc. - Common Stock
(NQ:
ARVN
)
9.930
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arvinas, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Forecasting The Future: 7 Analyst Projections For Arvinas
October 15, 2025
Via
Benzinga
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
October 15, 2025
Via
Benzinga
Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 15, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Arvinas
September 17, 2025
Via
Benzinga
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach
August 07, 2025
Via
Stocktwits
Earnings Scheduled For August 6, 2025
August 06, 2025
Via
Benzinga
What Analysts Are Saying About Arvinas Stock
June 02, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
May 01, 2025
Via
Benzinga
Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates
August 06, 2025
Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.
Via
Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
June 18, 2025
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 09, 2025
Via
Benzinga
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
June 06, 2025
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Via
Benzinga
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 02, 2025
Via
Benzinga
Where Arvinas Stands With Analysts
May 05, 2025
Via
Benzinga
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
May 02, 2025
Via
Benzinga
Here are the top movers in Thursday's session.
May 01, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Top stock movements in today's session.
May 01, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Dow Surges Over 300 Points; McDonald's Posts Weak Revenue
May 01, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
May 01, 2025
Via
Benzinga
The market is filled with gapping stocks in Thursday's session.
May 01, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via
Chartmill
Nasdaq Jumps 1.5%; Microsoft Posts Upbeat Results
May 01, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
May 01, 2025
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 01, 2025
Via
Benzinga
A Peek at Arvinas's Future Earnings
April 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 30, 2025
Via
Benzinga
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
April 04, 2025
Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.
Via
Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Month
March 26, 2025
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
March 12, 2025
Via
Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
March 12, 2025
Via
Benzinga
Tuesday's session: top gainers and losers
March 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.